Feasibility of ABUS as an Alternative to Handheld Ultrasound for Response Control in Neoadjuvant Breast Cancer Treatment



      The Invenia Automated Breast Ultrasound Screening (ABUS) is indicated as an adjunct to mammography for breast cancer screening in asymptomatic women with high-density breast tissue. ABUS provides time-efficient evaluation of the 3-dimensional recordings within 3 to 6 minutes. The role and advantages of ABUS in everyday clinical practice, especially in routine examination during neoadjuvant chemotherapy (NACT), is not clear. The aim of this monocentric, noninterventional retrospective study is to evaluate the use of ABUS in patients who are under NACT treatment for response control.


      Regular sonographic response check with handheld ultrasound (HHUS) examination and with ABUS were conducted in 83 women who underwent NACT. The response controls were conducted every 3 to 6 weeks during NACT. The handheld sonography was performed with GE Voluson S8. Handheld sonographic measurements and ABUS measurements were compared with the final pathologic tumor size.


      There was no statistical difference between the measurements with HHUS examination or ABUS compared with final pathologic tumor size (P = .47). The average difference from ABUS measured tumor size to final pathologic tumor size was 9.8 mm. The average difference from handheld measured tumor size to final pathologic tumor size was 9/3 mm. Both the specificity of ABUS and HHUS examination in predicting pathologic complete remission was 100%.


      ABUS seems to be a suitable method to conduct response control in neoadjuvant breast cancer treatment. ABUS may facilitate preoperative planning and offers remarkable time saving for physicians compared with HHUS examination and thus should be considered for clinical practice


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Clinical Breast Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Teshome M
        • Hunt KK.
        Neoadjuvant therapy in the treatment of breast cancer.
        Surg Oncol Clin N Am. 2014; 23: 505-523
        • Killelea BK
        • Yang VQ
        • Mougalian S,
        • et al.
        Neoadjuvant chemotherapy for breast cancer increases the rate of breast conservation. Results from the National Cancer Database.
        J Am Coll Surg. 2015; 220: 1063-1069
        • Colomer R
        • Saura C
        • Sánchez-Rovira P,
        • et al.
        Neoadjuvant management of early breast Cancer. A clinical and investigational position statement.
        Oncologist. 2019; 24: 603-611
        • Untch M
        • Minckwitz G von
        Neoadjuvant chemotherapy. Early response as a guide for further treatment: clinical, radiological, and biological.
        J Natl Cancer Inst Monographs. 2011; 2011: 138-141
        • Shin HJ
        • Kim HH
        • Ahn JH,
        • et al.
        Comparison of mammography, sonography, MRI and clinical examination in patients with locally advanced or inflammatory breast cancer who underwent neoadjuvant chemotherapy.
        Br J Radiol. 2011; 84: 612-620
        • Evans A
        • Whelehan P
        • Thompson A,
        • et al.
        Prädiktion der pathologischen Komplettremission nach neoadjuvanter Chemotherapie bei primärem Mammakarzinom mittels Interim Ultraschall, Shearwave-Elastografie und MRT.
        Ultraschall Med. 2018; 39: 422-431
        • Hayashi M
        • Yamamoto Y
        • Iwase H.
        Clinical imaging for the prediction of neoadjuvant chemotherapy response in breast cancer.
        Chin Clin Oncol. 2020; 9: 31
        • Khairalseed M
        • Javed K
        • Jashkaran G,
        • et al.
        Monitoring Early Breast Cancer Response to Neoadjuvant Therapy Using H-Scan Ultrasound Imaging. Preliminary Preclinical Results.
        J Ultrasound Med. 2019; 38: 1259-1268
        • Croshaw R
        • Shapiro-Wright H
        • Svensson E,
        • et al.
        Accuracy of clinical examination, digital mammogram, ultrasound, and MRI in determining postneoadjuvant pathologic tumor response in operable breast cancer patients.
        Ann Surg Oncol. 2011; 18: 3160-3163
        • Schott AF
        • Roubidoux MA
        • Helvie MA,
        • et al.
        Clinical and radiologic assessments to predict breast cancer pathologic complete response to neoadjuvant chemotherapy.
        Breast Cancer Res Treat. 2005; 92: 231-238
        • Peintinger F
        • Kuerer HM
        • Anderson K,
        • et al.
        Accuracy of the combination of mammography and sonography in predicting tumor response in breast cancer patients after neoadjuvant chemotherapy.
        Ann Surg Oncol. 2006; 13: 1443-1449
        • McGuire KP
        • Toro-Burguete J
        • Dang H,
        • et al.
        MRI staging after neoadjuvant chemotherapy for breast cancer. Does tumor biology affect accuracy?.
        Ann Surg Oncol. 2011; 18: 3149-3154
        • Keune JD
        • Jeffe DB
        • Schootman M,
        • et al.
        Accuracy of ultrasonography and mammography in predicting pathologic response after neoadjuvant chemotherapy for breast cancer.
        Am J Surg. 2010; 199: 477-484
        • Chagpar AB
        • Middleton LP
        • Sahin AA,
        • et al.
        Accuracy of physical examination, ultrasonography, and mammography in predicting residual pathologic tumor size in patients treated with neoadjuvant chemotherapy.
        Ann Surg. 2006; 243: 257-264
      1. GE Healthcare Company. InveniaTM ABUS. Available at:

      2. D'Orsi CJ, Sickles EA, Mendelson EB, Morris EA, , et al. ACR BI-RADS® Atlas, Breast Imaging Reporting and Data System. Available at:

        • Joekel J
        • Eggemann H
        • Costa SD,
        • et al.
        Should the hyperechogenic halo around malignant breast lesions be included in the measurement of tumor size?.
        Breast Cancer Res Treat. 2016; 156: 311-317
      3. GE Healthcare Company. Invenia ABUS 2.0. Available at:

        • Piotrzkowska-Wróblewska H
        • Dobruch-Sobczak K
        • Klimonda Z,
        • et al.
        Monitoring breast cancer response to neoadjuvant chemotherapy with ultrasound signal statistics and integrated backscatter.
        PLoS One. 2019; 14e0213749
        • Rauch GM
        • Adrada BE
        • Kuerer HM,
        • et al.
        Multimodality imaging for evaluating response to neoadjuvant chemotherapy in breast cancer.
        AJR Am J Roentgenol. 2017; 208: 290-299
        • Wojcinski S
        • Gyapong S
        • Farrokh A,
        • et al.
        Diagnostic performance and inter-observer concordance in lesion detection with the automated breast volume scanner (ABVS).
        BMC Med Imaging. 2013; 13: 36